Clinical trial
Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR…
NCT00073463 · Targeted Genetics Corporation, Industry · Terminated
Key facts
| NCT number | NCT00073463 |
|---|---|
| Title | Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis |
| Official title | A Multicenter, Double-Blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis |
| Lead sponsor | Targeted Genetics Corporation, Industry |
| Collaborators | Cystic Fibrosis Foundation |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Genetic |
| Interventions | tgAAVCF |
| Enrollment | 100 |
| Start date | Jun 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Nov 25, 2003 |
| Last update posted | Jan 28, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: